Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 245

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 245
---
3000
    or any other future compounds we may develop, including the costs and timing of establishing product sales, medical affairs,
    marketing, distribution and manufacturing capabilities;

    ●
    subject to receipt
    of marketing approval, if any, revenue received from commercial sale of CC8464, CT2000, CT3000 or any of our other future
    compounds;

    ●
    the terms and timing
    of any future collaborations, licensing, consulting or other arrangements that we may establish;

    ●
    the amount and timing
    of any payments we may be required or decide to make, or that we may receive, in connection with the licensing, filing, prosecution,
    maintenance, and enforcement of any patents or other intellectual property rights and defense against third party intellectual
    property infringement claims, including milestone and royalty payments and patent prosecution fees that we are obligated to
    pay pursuant to our license agreements, if any;

    ●
    the development
    of alternative treatments for EM or iSFN or other pain indications;

    ●
    our ability to establish
    and maintain collaborations and licenses on favorable terms, if at all; and

    ●
    the extent to which
    we acquire or in-license other compounds and technologies.

Identifying
potential compounds and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process
that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and
achieve product sales. Our lead compounds, if approved, may not achieve commercial success. Our future compound’s revenues,
if any, will be derived from or based on sales of compounds that may not be commercially available for many years, if at all.
Accordingly, it is unlikely that we will generate product or licensing revenue during the next twelve months and will need to
continue to rely on additional financing to achieve our business objectives. Any additional fundraising efforts may divert our
management from their day-to-day activities, which may adversely affect our ability to develop and commercialize future compounds.
Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional
securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline.
The sale of additional equity or convertible securities would dilute all our stockholders. The incurrence of indebtedness would
result in increased fixed payment obligations and a portion of our operating